News Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
27.49 ^USD	+1.18%		-4.35%	-34.75%

20/04	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT
20/04	Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	20/04	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	20/04	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	28/03	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	13/03	MT
Immunovant Awarded U.S. Patent for IMVT-1402	12/03	AQ
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	24/02	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	20/02	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	15/02	MT
Immunovant Posts Narrower Fiscal Q3 Loss	12/02	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023	12/02	AQ
North American Morning Briefing : Stock Futures -2-	09/02	DJ
North American Morning Briefing : Jobs Report Tops -2-	02/02	DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	30/01	MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	09/01
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	21/12	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	21/12	MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	21/12	DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	21/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunovant, Inc.

Equities

IMVT

US45258J1025

Summary

Filters